FINAL HOURS: Lock in your InvestingPro subscription for 50% off before sale ends
IRVINE, Calif. - Biomerica, Inc. (NASDAQ: BMRA), a small-cap biomedical company with a market capitalization of $7.92 million and current share price of $3.19, announced today that a clinical trial featured in the June 2025 issue of Gastroenterology has demonstrated the effectiveness of its inFoods® IBS test in managing symptoms of Irritable Bowel Syndrome (IBS). According to InvestingPro analysis, the company maintains a strong balance sheet with more cash than debt, positioning it well for continued product development. The study, described as a randomized, multicenter, double-blind, placebo-controlled trial, found that patients following a diet eliminating foods identified by the test experienced significant improvements in symptoms, especially abdominal pain and bloating.
The trial involved 238 IBS patients across eight U.S. academic centers, including the Mayo Clinic and Cleveland Clinic. Results showed that 59.6% of patients in the treatment group met the FDA responder definition for abdominal pain reduction, as opposed to 42.2% in the control group. Notably, among IBS-M patients, who currently have no FDA-approved drug treatments, 66.0% achieved symptom relief following the test-guided diet compared to 29.5% on a placebo diet.
The inFoods IBS test employs a proprietary assay to measure immune responses to a panel of foods, aiming to identify specific dietary triggers of IBS symptoms. Unlike traditional IgG food tests, this test is clinically validated for IBS and uses p-value associations and 95% confidence thresholds to provide personalized dietary recommendations. While the company shows promising revenue growth of 5.01% and maintains a healthy current ratio of 3.76, InvestingPro data reveals additional insights about the company’s financial health. Subscribers can access over 6 more exclusive ProTips and detailed financial metrics.
Dr. Anthony Lembo, Vice Chair of Research at Cleveland Clinic’s Digestive Disease Institute, highlighted the complexity of diets and the challenge of pinpointing individual food triggers. He stated that the inFoods IBS test offers a data-driven approach to help patients reduce symptoms by identifying specific problematic foods.
Biomerica, a global biomedical technology company, focuses on developing diagnostic and therapeutic products for gastrointestinal and inflammatory diseases. The inFoods IBS test is part of their mission to enhance health and well-being while aiming to reduce healthcare costs. With a gross profit margin of 13.42% and current undervaluation according to InvestingPro Fair Value metrics, the company presents an interesting case for investors following the biotech sector. Dive deeper into Biomerica’s potential with an InvestingPro subscription, which offers comprehensive financial analysis and exclusive insights.
This announcement is based on a press release statement from Biomerica, Inc., with further details available in the June 2025 issue of Gastroenterology.
In other recent news, Biomerica, Inc. has received approval from the United Arab Emirates Ministry of Health and Prevention to market its Fortel Ulcer Test, a diagnostic tool for detecting Helicobacter pylori infections. This test, which delivers results in 10 minutes, is part of Biomerica’s expansion in the Middle East and aims to aid in the early detection of conditions like peptic ulcers and gastric cancer. Additionally, Biomerica has gained approval to sell its Fortel® Kidney Disease Test in the UAE, designed to detect early signs of kidney damage. This test is particularly relevant given the high prevalence of diabetes and hypertension in the region, which are major risk factors for chronic kidney disease.
Moreover, Biomerica announced a 1-for-8 reverse stock split to comply with Nasdaq’s minimum bid price requirement. This action will consolidate every eight shares of pre-split stock into one post-split share, reducing the total outstanding shares from approximately 20.4 million to 2.5 million. The reverse stock split was authorized by shareholders and is part of Biomerica’s broader strategy to maintain its listing status. These developments highlight Biomerica’s ongoing efforts to expand its product reach and ensure compliance with stock market requirements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.